By employing two distinct aptamers targeting the characteristic proteins of exosomes (CD63, EpCAM), the synergistic effect of the dual aptamers enabled the precise capture of breast cancer exosomes and minimized the interference from nonspecific binding. The gene discussed is CD63; the disease is breast carcinoma.